Jones Financial Companies
CLRB icon

Jones Financial Companies’s Cellectar Biosciences CLRB Stock Holding History

Jones Financial Companies’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8 Hold
3
– – ﹤0.01% 4938
2026
Q1 		$8 Hold
3
– – ﹤0.01% 4704
2025
Q4 		$9 Hold
3
– – ﹤0.01% 4378
2025
Q3 		$17 Hold
3
– – ﹤0.01% 4203
2025
Q2 		$24 Buy
+3
New +$26 ﹤0.01% 3994

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.65% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Jones Financial Companies's CLRB Position: Q2 2026 in Review

Jones Financial Companies held its Cellectar Biosciences (CLRB) position steady in Q2 2026 at 3 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #4938.

Jones Financial Companies first reported a position in CLRB in Q2 2025 and has held it in 5 quarters since. The position peaked at $24 in Q2 2025. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Jones Financial Companies held 3 shares of Cellectar Biosciences worth $8 as of Q2 2026.
  • Jones Financial Companies left its Cellectar Biosciences share count unchanged in Q2 2026.
  • Cellectar Biosciences made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4938 holding.
  • Jones Financial Companies first reported a position in Cellectar Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's Cellectar Biosciences position peaked at $24 in Q2 2025.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.